More Than a CDMO
The End-to-End Support of Your Portfolio
Pre-Clinical
Partner with us for cell line and strain development, manufacturability assessments, cell banking and toxicology material generation. Let us guide your path to IND/IMPD submission.
Clinical Phase I, II
Partner with us to develop your initial clinical process for cGMP drug substance and drug product manufacturing.
Clinical Phase III
Partner with us to optimize, scale and characterize your process to meet anticipated therapeutic demands.
Commercialization
Partner with us for process validation and process performance qualification. Leverage our CMC and regulatory services for your BLA/MAA submission and experience our reliability.
Setting New Standards in Tomorrow’s Medicines
0
Billion USD Invested
in recent years
Spotlight
FUJIFILM Biotechnologies today announced the appointment of Christiane Bardroff as Chief Business Officer (CBO), effective June 1, 2026.
Launching at the Festival of Biologics, ShunzymeX is designed to streamline process development and accelerate GMP readiness for complex biologics.
Press Releases
FUJIFILM Biotechnologies Unveils Biomanufacturing and Process Development Expansion in the United Kingdom
FUJIFILM Biotechnologies expanded manufacturing and process development presence in the North East of England to support vital biomanufacturing innovative medicines and vaccines in the United Kingdom.
